Expertin
Univ Doz Dr Birgit Reipert

Expertise

  • Biologie, Botanik, Zoologie: Immunologie
  • Pharmazie, Pharmakologie, Toxikologie: Präklinische Testung neuer Pharmaka
  • Innovationsforschung: Identifizierung neuer Targets für potentiell immunmodulatorische neue Pharmaka

Verfügbar für

    Kooperationen
    Mentoring
    Projektleitung
    Projektmitarbeit

Ausbildung

Universität (1981)
Pharmazie, Pharmakologie, Toxikologie

Zusatzausbildung(en)
PhD in Immunologie 1984 Habilitation in Gefäßbiologie und Thromboseforschung 2005

Sprachen

  • Deutsch
  • Englisch
Mehr Details
  • Deutsch

    Schriftlich: Muttersprache / wie Muttersprache
    Konversation: Muttersprache / wie Muttersprache

  • Englisch

    Schriftlich: Muttersprache / wie Muttersprache
    Konversation: Muttersprache / wie Muttersprache

Referenzen

Auszeichnungen / Preise

2001:
Baxter Technical Award for Special Accomplishments
für Studien zur Immunogenicity of human factor VIII in murine hemophilia

2005:
Nachwuchsförderpreis 2005 - Bluterkrankheiten der Gesellschaft für Thrombose und Hämostaseforschung (Österreich, Deutschland, Schweiz) für Christina Hausl, eine meiner PhD-Studentinnen

Publikationen

Hausl C, Ahmad RU, Sasgary M, Doering CB, Lollar P, Richter G, Schwarz HP, Turecek PL, Reipert BM (2005): High dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Blood Aug 9 (Epub ahead of print)

Hausl C, Ahmad RU, Schwarz HP, Turecek PL, Dorner F, Reipert B (2004): Preventing re-stimulation of memory B cells in hemophilia A: A potential new strategy for the treatment of antibody-dependent immune diseases ?
Blood 104: 115-22. Epub 2004 Mar 04

Reipert BM, Schoppmann A, Schwarz HP (2003):
A caution on the use of murine hemophilia models for comparative immunogenicity studies of FVIII products with different protein compositions
Thromb Haemost 89, 1110-12

Reipert BM, Schwarz HP (2002):
What can we learn from the immune response to human factor VIII in a mouse model of murine hemophilia A ?
Thromb Haemost 88, 374-5

Hausl C, Maier E, Schwarz HP, Ahmad RU, Turecek PL and Reipert BM (2002):
Long-term persistence of anti-factor VIII antibody secreting cells in hemophilic mice after treatment with human factor VIII
Thromb Haemost 87, 840-45

Sasgary M, Ahmad RU, Schwarz HP, Turecek PL and Reipert BM (2002):
Single cell analysis of factor VIII-specific T-cells in hemophilic mice after treatment with human factor VIII.
Thromb Haemost 87: 266-72

Reipert BM, Sasgary M, Ahmad RU, Auer W, Turecek PL, Schwarz HP (2001):
Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance
Thromb Haemost 86, 1345-52

Reipert, B.M, Ahmad, R.U., Turecek P.L. and Schwarz, H.P. (2000):
Characterization of antibodies induced by human factor VIII in a murine model of
Hemophilia A.
Thromb Haemost 84, 826-32

Olas K, Butterweck H, Teschner W, Schwarz HP, Reipert BM (2005): Immunomodulatory properties of human serum immunoglobulin A: anti-inflammatory and pro-inflammatory activities of human monocytes and peripheral blood mononuclear cells.
Clin Exp Immunol 140: 478-90

Reipert BM, Tanneberger S, Pannetta A, Bedosti M, Poell M, Zimmermann K and Stellamor MT (2005): Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer?
Cancer Immunol Immunother 54:1038-42, Epub 2005, April 28

Birgit Reipert
Univ Doz Dr Birgit Reipert

Baxter BioScience

Kontakt

Letzte Aktualisierung: 05.05.2023